Clinician Scientist Supporting NCI-funded Clinical Trials at the Medical College of Wisconsin Cancer Center

临床科学家在威斯康星医学院癌症中心支持 NCI 资助的临床试验

• 批准号: 10561882
• 负责人: Mehdi Hussain Hamadani
• 金额: $ 11.06万
• 依托单位: MEDICAL COLLEGE OF WISCONSIN
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10561882
• 关键词: Adult; Award; Blood; Bone Marrow Transplantation; Cancer Center; Cancer Patient; Cell Therapy; Clinic; Clinical; Clinical Cancer Center; Clinical Research; Clinical Trials; Clinical Trials Network; Data; Disease; Funding; Hematology; Industry; Institution; Leadership; Maintenance; Malignant - descriptor; Medical; Medicine; Monitor; National Cancer Institute; Operations Research; Outpatients; Patients; Play; Principal Investigator; Procedures; Process; Protocols documentation; Research; Research Personnel; Role; Safety; Scientist; Services; Specialist; Time; United States National Institutes of Health; Wages; Wisconsin; cancer clinical trial; cancer research center director; career; human subject; improved; inpatient service; medical schools; participant enrollment; professor; programs; success; therapy outcome; transplantation therapy

PROJECT SUMMARY This application seeks partial salary support for a clinician scientist who is a highly accomplished clinical trialist in the Cancer Center at the Medical College of Wisconsin (MCW). Mehdi Hamadani, MD, the applicant for this Research Specialist Award, is currently a Professor of Medicine and the Medical and Administrative Director of the Cancer Center’s Clinical Blood and Marrow Transplantation and Cellular Therapy Program (BMT/CT). As a clinician who devotes two days per week to outpatient malignant hematology clinics and seven to eight weeks per year to inpatient service, Hamadani’s practice includes ~700 active cancer patients, with 147 new patients seen and 49 BMT and CT procedures provided to his clinic patients in 2021. At the same time, Hamadani is an indispensable leader of the clinical research operations of the Cancer Center’s Clinical Trials Office (CTO) and a top accruer to trials. The applicant seeks 30% salary support for the effort he will continue to devote to champion, administer and conduct NCI-funded clinical trials in the MCW Cancer Center, while continuing to build on and improve the BMT/CT clinical research enterprise he has led since 2017. As Chair of the BMT/CT Disease-Oriented Team (DOT), Hamadani provides administrative, clinical and research oversight for the BMT/CT program’s extensive research portfolio, which consistently accrues the most patients among the 14 adult DOTs at the Cancer Center. As part of his institutional leadership duties, Hamadani facilitates the BMT/CT protocol review and activation process and oversees maintenance of ongoing clinical trials. The successes of the BMT/CT program are due in part to his prolific clinical research career, having conceived, launched and conducted over 70 investigator- initiated, cooperative group, and industry-sponsored trials as local or national principal investigator. At the national level, Hamadani plays an active and instrumental role in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), an NIH-funded initiative that conducts large multi-institutional trials to improve cellular therapy outcomes. As protocol officer for several BMT CTN trials, three of which are actively enrolling patients, Hamadani is responsible for scientific and regulatory oversight of Network protocols. Given the targeted expansion of NCI-funded clinical trials in the coming years, including those that fall under the BMT/CT program, Dr. Hamadani aims to implement initiatives that will expand and sustain BMT/CT clinical trials research. Support provided by this award would significantly facilitate such efforts and allow him to continue to devote substantial energy and effort to the successful conduct of NCI-funded clinical trials in the MCW Cancer Center.

项目摘要 此应用程序寻求部分工资支持的临床科学家谁是一个非常成功的临床试验 在威斯康星州医学院的癌症中心（MCW）。Mehdi Hamadani，医学博士，申请人 研究专家奖，目前是医学教授和医疗和行政总监， 癌症中心的临床血液和骨髓移植和细胞治疗计划（BMT/CT）。作为 一位临床医生每周花两天时间在恶性血液病门诊， 每年到住院服务，Hamadani的诊所包括约700名活跃的癌症患者，其中有147名新患者 于2021年，他曾为诊所病人进行49次骨髓移植及电脑断层扫描。与此同时，Hamadani是一个 癌症中心临床试验办公室（CTO）临床研究运营不可或缺的领导者， 审判的最佳累积者 申请人寻求30%的工资支持，他将继续致力于冠军，管理和 在MCW癌症中心进行NCI资助的临床试验，同时继续建立和改善 自2017年以来，他一直领导BMT/CT临床研究企业。作为BMT/CT疾病导向团队的主席 (DOT)，Hamadani为BMT/CT项目的广泛研究提供行政，临床和研究监督 研究组合，其中一贯积累的14个成人DOT在癌症中心的最多的患者。 作为其机构领导职责的一部分，Hamadani促进了BMT/CT方案的审查和启动 处理并监督正在进行的临床试验的维护。BMT/CT计划的成功是由于 他丰富的临床研究生涯的一部分，已经构思，启动和进行了70多名研究者， 作为当地或国家主要研究者参与发起的、合作组和行业申办的试验。在 在国家一级，滨谷在血液和骨髓移植临床试验中发挥着积极的作用 网络（BMT CTN），一个NIH资助的计划，进行大型多机构试验，以改善细胞 治疗结果。作为几项BMT CTN试验的方案官员，其中三项正在积极招募患者， Hamadani负责网络协议的科学和监管监督。鉴于目标 在未来几年扩大NCI资助的临床试验，包括那些属于BMT/CT计划的临床试验， 博士Hamadani的目标是实施将扩大和维持BMT/CT临床试验研究的举措。支持 这一奖项提供的将大大促进这些努力，并允许他继续投入大量的 在MCW癌症中心成功开展NCI资助的临床试验。